In situ forming phase-inversion implants for sustained ocular delivery of triamcinolone acetonide

• Published in: Drug Delivery and Translational Research
• Main Author: Sheshala R.; Hong G.C.; Yee W.P.; Meka V.S.; Thakur R.R.S.
• Format: Article
• Language: English
• Published: Springer Verlag 2019
• Online Access: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85063632167&doi=10.1007%2fs13346-018-0491-y&partnerID=40&md5=264b0e9219488b45dc7990c61e48ab6c

The objectives of this study were to develop biodegradable poly-lactic-co-glycolic acid (PLGA) based injectable phase inversion in situ forming system for sustained delivery of triamcinolone acetonide (TA) and to conduct physicochemical characterisation including in vitro drug release of the prepared formulations. TA (at 0.5%, 1% and 2.5% w/w loading) was dissolved in N-methyl-2-pyrrolidone (NMP) solvent and then incorporated 30% w/w PLGA (50/50 and 75/25) polymer to prepare homogenous injectable solution. The formulations were evaluated for rheological behaviour using rheometer, syringeability by texture analyser, water uptake and rate of implant formation by optical coherence tomography (OCT) microscope. Phase inversion in situ forming formulations were injected into PBS pH 7.3 to form an implant and release samples were collected and analysed for drug content using a HPLC method. All formulations exhibited good syringeability and rheological properties (viscosity: 0.19–3.06 Pa.s) by showing shear thinning behaviour which enable them to remain as free-flowing solution for ease administration. The results from OCT microscope demonstrated that thickness of the implants were increased with the increase in time and the rate of implant formation indicated the fast phase inversion. The drug release from implants was sustained over a period of 42 days. The research findings demonstrated that PLGA/NMP-based phase inversion in situ forming implants can improve compliance in patient’s suffering from ocular diseases by sustaining the drug release for a prolonged period of time and thereby reducing the frequency of ocular injections. © 2018, Controlled Release Society.